X0306 4 2015-12-30 false 0001515673 Ultragenyx Pharmaceutical Inc. RARE 0001248093 KAKKIS EMIL D C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949 true true false false President & CEO Common Stock 2015-12-30 4 S false 2837.00 113.30 D 592803.00 D Common Stock 2015-12-30 4 S false 5465.00 114.61 D 587338.00 D Common Stock 2015-12-30 4 S false 3600.00 115.56 D 583738.00 D Common Stock 2015-12-30 4 S false 2600.00 116.31 D 581138.00 D Common Stock 2015-12-31 4 S false 2191.00 112.91 D 578947.00 D Common Stock 2015-12-31 4 S false 2702.00 113.83 D 576245.00 D Common Stock 2015-12-31 4 S false 605.00 114.61 D 575640.00 D Common Stock 2552241.00 I By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.00 to $114.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.08 to $115.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.10 to $116.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.34 to $113.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.43 to $114.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.44 to $114.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Shalini Sharp by power of attorney for Emil D. Kakkis, M.D., Ph.D. 2016-01-04